Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.47 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16316310 | 0.91 | KMT2A (0.61) | KMT2AMEN1CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL19057368 | 0.88 | KMT2A (0.58) | KMT2AMEN1CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL6033392 | 0.87 | MEN1 (0.64) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL17663571 | 0.84 | KMT2A (0.54) | KMT2AMEN1CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL4577891 | 0.84 | CYP1A2 (0.49) | KMT2ACYP2D6CYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL4577893 | 0.84 | CYP1A2 (0.49) | KMT2AMEN1CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL20249044 | 0.84 | CYP1A2 (0.49) | KMT2AMEN1CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL11028511 | 0.84 | CYP1A2 (0.49) | KMT2AMEN1CYP2D6CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL5041929 | 0.83 | CYP3A4 (0.50) | KMT2AMEN1CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL15468358 | 0.83 | CASP2 (0.53) | KMT2AMEN1CYP2D6CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4326067-A | FROM OXAZOLINE WITH AN AMINE | THE DOW CHEMICAL COMPANY (US) | 1982-04-20 | — | — | US | claimed |
| WO-2021243040-A2 | SMALL MOLECULE INHIBITORS OF GRK5 AND GRK5 SUBFAMILY MEMBERS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-12-02 | — | — | WO | disclosed |
| EP-2252605-B1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | INST NAT SANTE RECH MED (FR) | 2018-06-13 | — | — | EP | disclosed |
| US-20160139136-A1 | RAPID FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES WITH ENHANCED MS SIGNALS | WATERS TECHNOLOGIES CORPORATION (US) | 2016-05-19 | — | — | US | disclosed |
| US-8809341-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-1616899-B2 | Novel photoreactive polymers | AGFA GRAPHICS NV (BE) | 2014-07-02 | — | — | EP | disclosed |
| EP-2410987-A1 | METHODS OF TREATMENT USING COMBINATION THERAPY | Ambit Biosciences Corporation (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110190271-A1 | 2,4-Pyrimidinediamine Compounds and Uses as Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110178396-A1 | Nicotinamide Derivatives | CRC FOR BIOMEDICAL IMAGING DEVELOPMENT LTD. (AU) | 2011-07-21 | — | — | US | disclosed |
| US-7884111-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| EP-0027952-B1 | PROCESS FOR PREPARING N,O-DISUBSTITUTED URETHANES | BAYER AG (DE) | 1983-04-13 | — | — | EP | disclosed |
| EP-0027953-B1 | PROCESS FOR PREPARING N,O-DISUBSTITUTED URETHANES | BAYER AG (DE) | 1983-02-16 | — | — | EP | disclosed |
| EP-0028331-B1 | Process for preparing urethanes | BAYER AG (DE) | 1982-12-15 | — | — | EP | disclosed |
| EP-0060476-A2 | Process for the preparation of N substituted di and/or polyurethanes | BAYER AG (DE) | 1982-09-22 | — | — | EP | disclosed |
| EP-0059400-A2 | Process for the preparation of urethanes | BAYER AG (DE) | 1982-09-08 | — | — | EP | disclosed |
| US-4326067-A | FROM OXAZOLINE WITH AN AMINE | THE DOW CHEMICAL COMPANY (US) | 1982-04-20 | — | — | US | disclosed |
| EP-0028331-A1 | Process for preparing urethanes | BAYER AG (DE) | 1981-05-13 | — | — | EP | disclosed |
| EP-0027952-A1 | Process for preparing N,O-disubstituted urethanes | BAYER AG (DE) | 1981-05-06 | — | — | EP | disclosed |
| EP-0027940-A1 | Process for preparing urethanes | BAYER AG (DE) | 1981-05-06 | — | — | EP | disclosed |
| EP-0027953-A1 | Process for preparing N,O-disubstituted urethanes | BAYER AG (DE) | 1981-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190271-A1 | 2,4-Pyrimidinediamine Compounds and Uses as Anti-Proliferative Agents | MKI67, TYMP, PCNA | KMT2A 999/4885MEN1 2048/4885CYP2D6 3385/4885 |
| US-20160139136-A1 | RAPID FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES WITH ENHANCED MS SIGNALS | FUT5, FUT6, CSGALNACT1 | KMT2A 3081/4885MEN1 2746/4885CYP2D6 3838/4885 |
| US-20110178396-A1 | Nicotinamide Derivatives | NAMPT, NNT, NNMT | KMT2A 1010/4885MEN1 330/4885CYP2D6 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.